NEVRO CORP (NVRO) Stock Price, Quote, News and Overview
NYSE:NVRO - New York Stock Exchange, Inc. - US64157F1030 - Common Stock - Currency: USD
NVRO Quote, Performance and Key Statistics
NEVRO CORP
NYSE:NVRO (2/12/2025, 1:34:16 PM)
5.72
0 (0%)
The current stock price of NVRO is 5.72 USD. In the past month the price increased by 41.94%. In the past year, price decreased by -66.97%.
NVRO Latest News and Analysis
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders
NVRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.88 | 225.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.59 | 210.40B | ||
| BSX | BOSTON SCIENTIFIC CORP | 42.12 | 155.80B | ||
| SYK | STRYKER CORP | 31.71 | 147.35B | ||
| MDT | MEDTRONIC PLC | 17.43 | 117.35B | ||
| BDX | BECTON DICKINSON AND CO | 17.27 | 65.93B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.65 | 44.27B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.35 | 39.23B | ||
| IDXX | IDEXX LABORATORIES INC | 40.46 | 37.27B | ||
| RMD | RESMED INC | 26.79 | 34.77B | ||
| DXCM | DEXCOM INC | 49.59 | 32.93B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 21.11 | 26.39B |
Related stock screener links
About NVRO
Company Profile
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,215 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Company Info
NEVRO CORP
1800 Bridge Parkway
Redwood City CALIFORNIA 94065 US
CEO: D. Keith Grossman
Employees: 1215
Company Website: https://www.nevro.com
Investor Relations: https://nevro.com/English/us/investors/
Phone: 16502510005
NVRO FAQ
What is the stock price of NVRO?
The current stock price of NVRO is 5.72 USD.
What is the symbol for NEVRO CORP stock?
The exchange symbol of NEVRO CORP is NVRO and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is NVRO stock listed?
NVRO stock is listed on the New York Stock Exchange, Inc. exchange.
Is NVRO a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NVRO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NVRO.
Does NVRO stock pay dividends?
NVRO does not pay a dividend.
When does NVRO stock report earnings?
NVRO will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of NVRO?
NVRO does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
What is the Short Interest ratio of NVRO stock?
The outstanding short interest for NVRO is 7.88% of its float.
NVRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NVRO. When comparing the yearly performance of all stocks, NVRO is a bad performer in the overall market: 86.58% of all stocks are doing better.
NVRO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVRO. Both the profitability and financial health of NVRO have multiple concerns.
NVRO Financial Highlights
Over the last trailing twelve months NVRO reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 38.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.64% | ||
| ROE | -25.33% | ||
| Debt/Equity | 0.81 |
NVRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to NVRO. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 3.56% and a revenue growth -4.09% for NVRO